PMV Pharma Q1 net loss $18M; rezatapopt NDA for ovarian cancer targeted for Q1 2027

PMV Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.34

Cash and securities $93.5M at March 31, 2026; net cash used in operations $19.7M for Q1.
Net loss $18M for Q1 2026 vs $17.4M in Q1 2025; R&D expenses decreased to $15.3M.
Confirmed ORR 44% (32/72) for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer from SGO April 2026.
FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian cancer.
Phase 1 results published in NEJM; NDA submission planned in Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2026, was $18 million compared to $17.4 million for the quarter ended March 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

PMV Pharma ended the first quarter with $93.5 million in cash, cash equivalents, and marketable securities, compared to $112.9 million as of December 31, 2025.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.